The short version of GLP-1 receptor fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-08-22. Anything still debated is marked as such rather than presented as settled.
Stability studies examine how temperature, pH, and moisture influence degradation rates over time. In aqueous solution, hydrolysis and deamidation accelerate as pH moves away from mildly acidic conditions. Light exposure and residual metal ions can also trigger oxidation of susceptible residues. Accelerated aging at elevated temperature is used to estimate shelf life, though extrapolation to room temperature carries uncertainty because individual degradation pathways do not always scale predictably.
Lyophilized semaglutide powder is typically held at minus twenty degrees Celsius for long-term storage. At that temperature, solid-state degradation reactions proceed slowly and the peptide remains intact for extended periods. Repeated freeze-thaw cycles are best avoided because they promote aggregation and can shift the proportion of monomeric peptide present. Working aliquots are often prepared so that each portion is thawed only once, and desiccant is placed inside the vial to limit moisture uptake.
Identity and purity are usually assessed by reverse-phase high-performance liquid chromatography coupled to mass spectrometry. Retention time and observed mass are compared against a reference standard run under identical conditions. Impurity profiles reveal deamidation products, oxidized methionine variants, and truncated fragments that arise during synthesis or storage. Peptide mapping through enzymatic digestion confirms the primary sequence, while amino acid analysis offers an independent check on overall composition.
The sequence incorporates alpha-aminoisobutyric acid at position 8, replacing the alanine found in the natural hormone. This substitution blocks the primary DPP-4 recognition site and contributes most of the enzymatic stability. Albumin binding further protects the peptide and reduces the frequency of administration required to maintain active plasma levels. Because the fatty acid chain increases lipophilicity, the compound is formulated as a solution rather than a simple aqueous buffer. Researchers describe the design as an incremental optimization of earlier GLP-1 analogs rather than a wholly new scaffold.
Reported molecular weight is approximately 4113.6 daltons for the free base, and the peptide is supplied as a lyophilized powder or in buffered liquid form depending on the intended use. It is freely soluble in water when formulated with appropriate excipients, though the unconjugated peptide shows limited stability at neutral pH over long periods. Analytical characterization typically relies on reversed-phase high-performance liquid chromatography and mass spectrometry. Purity specifications for research-grade material commonly exceed ninety-five percent by area. Isotopic and impurity profiles differ between suppliers.
Two principal therapeutic variants exist under separate regulatory filings, one indicated for glycemic control in type 2 diabetes and one for chronic weight management. Both use the same active molecule; differences lie in formulation strength, titration schedule, and labeling. Regulatory agencies in the United States and European Union approved injectable forms in 2017 and 2018 respectively. An oral tablet formulation received approval later, using a carrier molecule to enhance absorption across the gastric epithelium. Labeling differs by jurisdiction and by indication.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white lyophilized powder | Batch-to-batch variation is normal |
| Solubility class | Soluble in water, buffer, and dimethyl sulfoxide | Aqueous solubility is moderate |
| Typical storage temperature | Minus 20 degrees Celsius dry, 2 to 8 degrees Celsius reconstituted | Avoid repeated freeze-thaw |
| Common analytical method | Reverse-phase HPLC with electrospray mass detection | Used for purity and mass confirmation |
| Common synonyms | GLP-1 analog, semaglutide peptide | Wording varies across suppliers |
Semaglutide is a synthetic peptide of thirty-one amino acids that shares roughly ninety-four percent sequence identity with human glucagon-like peptide-1. Two substitutions resist enzymatic cleavage by dipeptidyl peptidase-4, and a fatty diacid side chain attached through a linker promotes binding to serum albumin. That albumin binding slows renal clearance and extends the circulating half-life from minutes to approximately one week. The structural changes are well established in the published literature. Whether the same modifications affect receptor signalling bias in ways that matter clinically remains an open question.
Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1 (GLP-1), a hormone released from intestinal L-cells after food intake. The compound belongs to the incretin mimetic class and acts at GLP-1 receptors distributed across pancreatic, gastrointestinal, cardiovascular, and central nervous system tissues. Compared with native GLP-1, the molecule carries structural changes that extend its activity from minutes to roughly one week. It is studied for glycemic control in type 2 diabetes and for weight management, and its effects on cardiovascular and other outcomes remain active research areas.
Receptor binding triggers G protein signaling that raises intracellular cyclic AMP in pancreatic beta cells. Insulin release follows in a glucose-dependent manner, so secretion increases when blood glucose is elevated and diminishes when it is not. The same signaling suppresses glucagon release from alpha cells and slows gastric emptying, which blunts the post-meal glucose rise. In the brain, receptor activation in regions such as the arcuate nucleus is associated with reduced appetite and lower energy intake. How much each of these effects contributes to overall weight change is not fully settled.
Two structural features account for the prolonged half-life of semaglutide. A modified amino acid at position 8 resists cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GLP-1. A fatty diacid side chain binds serum albumin, which limits renal clearance and protects the peptide from enzymatic breakdown. These modifications yield a plasma half-life of approximately one week in humans, allowing once-weekly administration. The relationship between plasma concentration and clinical effect varies between individuals, and sources of that variability are still being characterized.
Activation of the GLP-1 receptor couples to Gs signalling and raises intracellular cyclic AMP in pancreatic beta cells. The resulting insulin release depends on prevailing glucose concentrations, so the effect is greater when glucose is elevated. Receptor engagement also suppresses glucagon secretion and slows gastric emptying, which flattens post-meal glucose excursions. In the central nervous system, signalling in hypothalamic and brainstem regions is associated with reduced appetite and lower energy intake. Studies continue to examine effects on cardiac, renal and hepatic endpoints; whether those benefits are independent of weight change remains an open question.
Clinical development of this compound followed earlier short-acting GLP-1 analogues that required frequent injection. Once-weekly subcutaneous formulations entered use after 2017, and an oral formulation using a permeation enhancer later became available. The oral version pairs the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier that improves uptake across the gastric epithelium. Interest has expanded from glycaemic control into weight management and metabolic liver disease. Regulatory status and approved indications differ between countries, and the product remains subject to ongoing safety monitoring.
Reverse-phase high-performance liquid chromatography is the standard method for purity assessment, separating the peptide from truncated or oxidized variants. Mass spectrometry confirms molecular mass and detects modifications, while ultraviolet absorbance near 280 nanometers supports concentration measurement through tryptophan and tyrosine residues. Circular dichroism can indicate secondary structure, though the peptide is largely helical in solution, and ion-exchange chromatography resolves charge variants. Purity values above 95 percent are typical for research-grade material. Stability studies track degradation over time under defined conditions.
Lyophilized semaglutide is typically stored at temperatures between minus 20 and minus 80 degrees Celsius for long-term preservation. Short-term storage at 2 to 8 degrees Celsius is common for working aliquots. Repeated freeze-thaw cycles can degrade the peptide and are usually avoided. The molecule is hygroscopic in its solid form, so containers should remain sealed with desiccant. Solutions are less stable than powders and are generally prepared fresh. Light exposure is limited because aromatic residues can undergo photo-oxidation.
Semaglutide dissolves readily in water and in aqueous buffers near neutral pH. Solubility decreases near the isoelectric point, where net charge is minimal. Common laboratory solvents include phosphate-buffered saline and dilute ammonium bicarbonate. Strongly acidic or basic conditions may accelerate hydrolysis. Working concentrations are usually prepared by diluting a concentrated stock. Vial surfaces can adsorb small amounts of peptide at low concentrations, so carrier proteins or low-binding tubes are sometimes used.
However, a 2021 study on the decay chains of flerovium isotopes suggests that there is no strong stabilizing effect from Z = 114 in the region of known nuclei (N = 174), and that extra stability would be predominantly a consequence of the neutron shell closure. Although known nuclei still fall several neutrons short of N = 184 where maximum stability is expected (the most neutron-rich confirmed nuclei, 293Lv and 294Ts, only reach N = 177), and the exact location of the center of the island remains unknown, the trend of increasing stability closer to N = 184 has been demonstrated. For example, the isotope 285Cn, with eight more neutrons than 277Cn, has a half-life almost five orders of magnitude longer. This trend is expected to continue into unknown heavier isotopes in the vicinity of the shell closure.
=== San Antonio Nathan Shock Center === The San Antonio Nathan Shock Center (NSC) is one of only eight National Institute on Aging (NIA)-funded Nathan Shock Centers of Excellence in the Basic Biology of Aging in the United States. Since its establishment in 1995, the Center has served as an internationally recognized resource dedicated to advancing the fundamental biology of aging and accelerating the development of interventions that promote healthy aging and extend healthspan. The overarching mission of the Center is to identify the molecular, cellular, and physiological mechanisms that drive the aging process and translate these discoveries into strategies that delay or prevent age-associated diseases and functional decline. The San Antonio Nathan Shock Center provides investigators with an integrated, "one-stop-shop" research infrastructure that supports every stage of aging research—from experimental design and animal model development to functional phenotyping, pathology, metabolism, pharmacology, and data interpretation. This comprehensive approach enables investigators to conduct rigorous, multidisciplinary studies that examine lifespan, healthspan, and the biological mechanisms underlying aging. By integrating specialized expertise and state-of-the-art technologies within a single research environment, the Center accelerates scientific discovery while promoting collaboration among investigators locally, nationally, and internationally. The Center is organized around six highly integrated research cores that provide specialized services and scientific expertise.
2019: New Zealand chemist Margaret Brimble is the first New Zealand woman to be inducted into the Division of Medicinal Chemistry of the American Chemical Society’s Hall of Fame. 2019: Malawian nurse and educator Address Malata is appointed as Vice-Chancellor of the Malawi University of Science and Technology (MUST), becoming the first Malawian women university Vice-Chancellor. 2019: American imaging scientist Katie Bouman developed an algorithm that made the first visualization of a black hole possible using the Event Horizon Telescope. She was part of the team of over 200 people who implemented the project.
=== Bab–Bar === Stephen Moulton Babcock (1843–1931), American agricultural chemist worked on the "single-grain experiment" Myrtle Bachelder (1908–1997), American chemist noted for work on the Manhattan Project atomic bomb, and for work on metal chemistry Werner Emmanuel Bachmann (1901–1951), American chemist, known for work in steroids and RDX Simone Badal-McCreath (21st century), Jamaican chemist who created prostate and breast cancer cell lines Leo Baekeland (1863–1944), Belgian-American chemist known for invention of bakelite Adolf von Baeyer (1835–1917), German chemist, 1905 Nobel Prize in Chemistry, synthesis of indigo Piero Baglioni (born 1952), Italian chemist known for inorganic and organic colloids Hendrik Willem Bakhuis Roozeboom (1854–1907), Dutch chemist who studied phase behaviour in physical chemistry Alice Ball (1892–1916), American chemist known for inventing an effective injectable treatment for leprosy Emily Balskus (born 1980), American chemist and microbiologist known for work on the human microbiome Zhenan Bao (born 1970), Chinese chemist known for developing technologies with organic field-effect transistors and organic semiconductors Phil S. Baran (born 1977), American chemist known for synthesis, novel reactions and reagents Coral Barbas (PhD 1989), Spanish chemist known for research on metabolomics and integration of chemical data Allen J.
Sources: en.wikipedia.org
Subarachnoid hemorrhage Increased blood pressure when combined with other medications that raise blood pressure, particularly when used prior to administering epidural anesthesia Cardiac arrhythmia including increased or decreased heart rate, and premature ventricular contraction Impaired uterine blood flow or excessive uterine contractions when combined with other medications that cause uterine contraction (carboprost, misoprostol) Uterine rupture Afibrinogenemia Anaphylaxis Nausea and vomiting Changes in fetal blood flow Many of these side effects are unable to be differentiated from the risks of normal labor versus oxytocin administration itself. Oxytocin during labour is associated with a significantly higher risk of severe postpartum hemorrhage. Excessive dosage or long-term administration (over a period of 24 hours or longer) has been known to result in tetanic uterine contractions, uterine rupture, sometimes fatal. Water intoxication may be exhibited in administration through symptoms such as seizures, comas, neonatal jaundice, and potential fatality. Managed fluid intake and consistent monitoring of sodium levels has been researched as crucial in the safe administration of oxytocin. The use of oxytocin during childbirth has been linked to an increased need for other medical interventions, most primarily, through the administration of an epidural anaesthetic. This has been documented as creating a 'cascade effect', potentially causing detrimental impacts to the birthing process. Oxytocin administration also, conversely, decreases the rate of cesarean sections.
horizontal gene transfer (HGT) Also lateral gene transfer (LGT). Any process by which genetic material is transferred between unicellular and/or multicellular organisms other than by vertical transmission from parent to offspring, e.g. bacterial conjugation.
=== Bombing of Laos === In February 1970, several senators led by J. William Fulbright and Stu Symington first learned that the United States had been bombing Laos since December 1964, which led to complaints in Congress about the "secret war" in Laos. Nixon reluctantly decided to admit to the "secret war", and directed Kissinger to issue the necessary statement to the media. Kissinger's statement admitted to the bombing of Laos, but also claimed: "No American stationed in Laos has ever been killed in ground combat operations". Two days later, it emerged that a U.S. Army captain had been killed while fighting in Laos and subsequently the Pentagon admitted that in the period February 1969-February 1970 a total of 27 Americans had been killed in Laos. Kissinger claimed that he had not lied, maintaining that all Americans killed in Laos were in "hot pursuit" when chasing the enemy from South Vietnam into Laos, but this argument made no impression. Nixon stated: "No one cares about B-52 strikes in Laos, but people worry about our boys out there". Nixon refused to see Kissinger for the next week, saying that his statement about Laos had caused him to drop 11 points in the public opinion polls.
Sources: en.wikipedia.org
Manufacturers commonly state multi-year stability when the powder is kept dry and frozen. Actual shelf life depends on residual moisture, vial sealing, and storage temperature. A re-test by chromatography is the only way to confirm remaining purity.
Deamidated and oxidized forms are the most frequently reported impurities. Truncated peptide fragments from incomplete synthesis also appear at low levels. Their relative abundance grows with time, heat exposure, and unfavorable pH.
Retention time matching on a validated column provides strong circumstantial evidence. It does not distinguish compounds with similar hydrophobicity. Mass measurement or peptide mapping is needed for unambiguous identification.
It is a modified version of the natural hormone, with three amino acid changes and a fatty acid side chain added. These edits extend its half-life from minutes to about one week. The core receptor activity is retained.